Bulk Manufacturer of Controlled Substances Application: Sterling Pharma USA, LLC, 8381 [2021-02455]
Download as PDF
<![CDATA[
8381
Federal Register / Vol. 86, No. 23 / Friday, February 5, 2021 / Notices
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,2 solely for cybersecurity
purposes. All nonconfidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.3
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of §§ 201.10 and 210.8(c) of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.8(c)).
comments on or objections to the
issuance of the proposed registration on
or before April 6, 2021. Such persons
may also file a written request for a
hearing on the application on or before
April 6, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on January 5, 2021,
Sterling Pharma USA, LLC., 1001
Sheldon Drive, Suite 101, Cary, North
Carolina 27513–2078, applied to be
registered as an bulk manufacturer of
the following basic class(es) of
controlled substance(s):
By order of the Commission.
Issued: February 1, 2021.
Lisa Barton,
Secretary to the Commission.
William T. McDermott,
Assistant Administrator.
Controlled substance
Drug
code
Schedule
Tetrahydrocannabinols ...............
7370
I
The company plans to manufacture in
bulk drug code 7370
(Tetrahydrocannabinols) exclusively
from hemp extract, for distribution and
sale to its customers. No other activity
for this drug code is authorized for this
registration.
[FR Doc. 2021–02455 Filed 2–4–21; 8:45 am]
BILLING CODE P
[FR Doc. 2021–02435 Filed 2–4–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Bulk Manufacturer of Controlled
Substances Application: Noramco, Inc.
[Docket No. DEA–772]
Bulk Manufacturer of Controlled
Substances Application: Sterling
Pharma USA, LLC
AGENCY:
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
SUMMARY:
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Sterling Pharma USA LLC has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
jbell on DSKJLSW7X2PROD with NOTICES
VerDate Sep<11>2014
18:53 Feb 04, 2021
Jkt 253001
Controlled substance
Gamma Hydroxybutyric Acid ....
Marihuana Extract .....................
Marihuana .................................
Tetrahydrocannabinols .............
Codeine-N-oxide .......................
Dihydromorphine .......................
Hydromorphinol .........................
Nabilone ....................................
Codeine .....................................
Dihydrocodeine .........................
Oxycodone ................................
Hydromorphone ........................
Hydrocodone .............................
Levorphanol ..............................
Morphine ...................................
Drug
code
Schedule
2010
7350
7360
7370
9053
9145
9301
7379
9050
9120
9143
9150
9193
9220
9300
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
The company plans to manufacture
bulk active pharmaceutical ingredients
(API) and reference standards for
distribution to their customers.
In reference to drug codes 7350
(Marihuana Extract), 7360 (Marihuana),
and 7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture
these drugs as synthetics. No other
activities for these drugs are authorized
for this registration.
William T. McDermott,
Assistant Administrator.
BILLING CODE P
Drug Enforcement Administration
2 All contract personnel will sign appropriate
nondisclosure agreements.
3 Electronic Document Information System
(EDIS): https://edis.usitc.gov.
In
accordance with 21 CFR 1301.33(a), this
is notice that on November 3, 2020,
Noramco Inc, 1550 Olympic Drive,
Athens Georgia 30601, applied to be
registered as an bulk manufacturer of
the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
[FR Doc. 2021–02454 Filed 2–4–21; 8:45 am]
[Docket No. DEA–771]
SUMMARY:
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
[OMB Number 1125–NEW]
Noramco Inc has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 6, 2021. Such persons
may also file a written request for a
hearing on the application on or before
April 6, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Agency Information Collection
Activities; Proposed Collection;
Comments Requested; FOIAXpress/
FOIA Public Access Link
Executive Office for
Immigration Review, Department of
Justice.
ACTION: 30-day notice.
AGENCY:
The Department of Justice
(DOJ), Executive Office for Immigration
Review (EOIR), will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
SUMMARY:
E:\FR\FM\05FEN1.SGM
05FEN1
]]>Agencies
[Federal Register Volume 86, Number 23 (Friday, February 5, 2021)]
[Notices]
[Page 8381]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02455]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-772]
Bulk Manufacturer of Controlled Substances Application: Sterling
Pharma USA, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Sterling Pharma USA LLC has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before April 6, 2021.
Such persons may also file a written request for a hearing on the
application on or before April 6, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on January 5, 2021, Sterling Pharma USA, LLC., 1001
Sheldon Drive, Suite 101, Cary, North Carolina 27513-2078, applied to
be registered as an bulk manufacturer of the following basic class(es)
of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols.................... 7370 I
------------------------------------------------------------------------
The company plans to manufacture in bulk drug code 7370
(Tetrahydrocannabinols) exclusively from hemp extract, for distribution
and sale to its customers. No other activity for this drug code is
authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-02455 Filed 2-4-21; 8:45 am]
BILLING CODE P
